Principles of risk assessment in colon cancer: immunity is key

References

• Rebuzzi SE, Pesola G, Martelli V, Sobrero AF. Adjuvant chemotherapy for stage II colon cancer. Cancers Basel. 2020;12(9):2584. doi:10.3390/cancers12092584. PMID: 32927771.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Puccini A, Shi Q, Grothey A, Andre T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:182–11. doi:10.1016/j.ejca.2020.07.031. PMID: 32892120.
   PubMed Web of Science ®Google Scholar
• Fang SH, Efron JE, Berho ME, Wexner SD. Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J Am Coll Surg. 2014;219:1056–1069. doi:10.1016/j.jamcollsurg.2014.09.010. PMID: 25440029.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, et al. Assessment of duration and effects of 3 vs 6 months of adjuvant chemotherapy in high-risk stage II colorectal cancer: a subgroup analysis of the TOSCA randomized clinical trial. JAMA Oncol. 2020;6:547–551. doi:10.1001/jamaoncol.2019.6486. PMID: 32053133.
   PubMed Web of Science ®Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet. 1995;345(8955):939–944. doi:10.1016/S0140-6736(95)90696-7. PMID: 7715291.
   PubMed Web of Science ®Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators. JCO. 1999;17(5):1356–1363. doi:10.1200/JCO.1999.17.5.1356. PMID: 10334519.
   PubMedGoogle Scholar
• Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–3407. doi:10.1200/JCO.2004.03.087. PMID: 15199087.
   PubMed Web of Science ®Google Scholar
• Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029. doi:10.1016/S0140-6736(07)61866-2. PMID: 18083404.
   PubMed Web of Science ®Google Scholar
• Babcock BD, Aljehani MA, Jabo B, Choi AH, Morgan JW, Selleck MJ, Luca F, Raskin E, Reeves ME, Garberoglio CA, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25:1980–1985. doi:10.1245/s10434-018-6484-8. PMID: 29675762.
   PubMed Web of Science ®Google Scholar
• Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29:4620–4626. doi:10.1200/JCO.2011.35.4498. PMID: 22067406.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011;10:73–80. doi:10.1016/j.clcc.2011.03.001. PMID: 21859557.
   PubMed Web of Science ®Google Scholar
• Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, Schuster T, Keller G, Zeestraten E, Goossens I, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Annals Surg. 2013;257:1053–1058. doi:10.1097/SLA.0b013e31827c1180. PMID: 23295318.
   PubMed Web of Science ®Google Scholar
• Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, et al. Validation study of a quantitative multigene reverse transcriptase–polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–4619. doi:10.1200/JCO.2010.32.8732. PMID: 22067390.
   PubMed Web of Science ®Google Scholar
• Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24. doi:10.1200/JCO.2010.30.1077. PMID: 21098318.
   PubMed Web of Science ®Google Scholar
• Varghese A. Chemotherapy for stage II colon cancer. Clin Colon Rectal Surg. 2015;28:256–261. doi:10.1055/s-0035-1564430. PMID: 26648796.
   PubMed Web of Science ®Google Scholar
• Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40:892–910. doi:10.1200/JCO.21.02538. PMID: 34936379.
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419. doi:10.1200/JCO.2004.05.063. PMID: 15199089.
   PubMed Web of Science ®Google Scholar
• Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, Cervantes A, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Huitzil FD, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2019;5(5):1–19. doi:10.1200/JGO.18.00214. PMID: 30802158.
   Google Scholar
• Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, et al. Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol. 2021;39:631–641. doi:10.1200/JCO.20.01330. PMID: 33439695.
   PubMed Web of Science ®Google Scholar
• Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54(1):5–16. doi:10.3109/0284186X.2014.975839. PMID: 25430983.
   PubMed Web of Science ®Google Scholar
• Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant chemotherapy for stage II colon cancer: practice patterns and effectiveness in the general population. Clin Oncol (R Coll Radiol). 2017;29(1):e29–e38. doi:10.1016/j.clon.2016.09.001. PMID: 27663601.
   PubMed Web of Science ®Google Scholar
• Gill S, Meyerhardt JA, Arun M, Veenstra CM. Translating IDEA to practice and beyond: managing stage II and III colon cancer. Am Soc Clin Oncol Educ Book. 2019;39(39):226–235. doi:10.1200/EDBK_237443. PMID: 31099666.
   PubMedGoogle Scholar
• Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, et al. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technol Assess. 2019;23:1–88. doi:10.3310/hta23640. PMID: 31852579.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T, et al. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol. 2021;32:77–84. doi:10.1016/j.annonc.2020.10.480. PMID: 33121997.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol. 2012;30(27):3353–3360. doi:10.1200/JCO.2012.42.5645. PMID: 22915656.
   PubMed Web of Science ®Google Scholar
• O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–3388. doi:10.1200/JCO.2010.34.3426. PMID: 21788561.
   PubMed Web of Science ®Google Scholar
• Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291–1305. doi:10.1016/j.annonc.2020.06.022. PMID: 32702383.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116. doi:10.1200/JCO.2008.20.6771. PMID: 19451431.
   PubMed Web of Science ®Google Scholar
• Bastos DA, Ribeiro SC, de Freitas D, Hoff PM. Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. Ther Adv Med Oncol. 2010;2(4):261–272. doi:10.1177/1758834010367905. PMID: 21789139.
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. JCO. 1995;13(12):2936–2943. doi:10.1200/JCO.1995.13.12.2936. PMID: 8523058.
   PubMed Web of Science ®Google Scholar
• Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017;357:55–60. doi:10.1126/science.aai8515. PMID: 28684519.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international study of the consensus immunoscore for the prediction of relapse and survival in early-stage colon cancer. Cancers Basel. 2023;15(2):418. doi:10.3390/cancers15020418. PMID: 36672367.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, et al. Clinical performance of the consensus immunoscore in colon cancer in the Asian population from the multicenter international SITC study. Cancers Basel. 2022;14(18):4346. doi:10.3390/cancers14184346. PMID: 36139506.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X. PMID: 29754777.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139. PMID: 17008531.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618. doi:10.1200/JCO.2010.30.5425. PMID: 21245428.
   PubMed Web of Science ®Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–5951. doi:10.1200/JCO.2008.19.6147. PMID: 19858404.
   PubMed Web of Science ®Google Scholar
• Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Nunez NG, Tosello Boari J, Richer W, Menger L, Denizeau J, et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022;185(7):1189–1207 e1125. doi:10.1016/j.cell.2022.02.021. PMID: 35325594.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7. PMID: 32753728.
   PubMed Web of Science ®Google Scholar
• Galon J, Sudarshan C, Ito S, Finbloom D, O’Shea JJ. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol. 1999;162(12):7256–7262. doi:10.4049/jimmunol.162.12.7256. PMID: 10358173.
   PubMed Web of Science ®Google Scholar
• Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLOS Med. 2013;10(5):e1001453. doi:10.1371/journal.pmed.1001453. PMID: 23700391.
   PubMed Web of Science ®Google Scholar
• Ghidini M, Fusco N, Salati M, Khakoo S, Tomasello G, Petrelli F, Trapani D, Petrillo A. The emergence of immune-checkpoint inhibitors in colorectal cancer therapy. Curr Drug Targets. 2021;22:1021–1033. doi:10.2174/1389450122666210204204415. PMID: 33563194.
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115. doi:10.1038/s41573-018-0004-1. PMID: 30470818.
   PubMed Web of Science ®Google Scholar
• Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, Kong SL, Chua C, Hon LK, Tan WS, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat Genet. 2017;49:708–718. doi:10.1038/ng.3818. PMID: 28319088.
   PubMed Web of Science ®Google Scholar
• Nigam M, Mishra AP, Deb VK, Dimri DB, Tiwari V, Bungau SG, Bungau AF, Radu AF. Evaluation of the association of chronic inflammation and cancer: insights and implications. Biomed Pharmacother. 2023;164:115015. doi:10.1016/j.biopha.2023.115015. PMID: 37321055.
   PubMed Web of Science ®Google Scholar
• Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. Nat Rev Clin Oncol. 2021;18:101–115. doi:10.1038/s41571-020-0422-y. PMID: 32901132.
   PubMed Web of Science ®Google Scholar
• Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25:1315–1325. doi:10.1038/modpathol.2012.94. PMID: 22790014.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261–2272. doi:10.1056/NEJMoa2200075. PMID: 35657320.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–2666. doi:10.1056/NEJMoa051424. PMID: 16371631.
   PubMed Web of Science ®Google Scholar
• Wang F, Lu S, Cao D, Qian J, Li C, Zhang R, Wang F, Wu M, Liu Y, Pan Z, et al. Prognostic and predictive value of immunoscore and its correlation with ctDNA in stage II colorectal cancer. Oncoimmunology. 2023;12:2161167. doi:10.1080/2162402X.2022.2161167. PMID: 36632564.
   PubMed Web of Science ®Google Scholar
• Boquet I, Kassambara A, Lui A, Tanner A, Latil M, Lovera Y, Arnoux F, Hermitte F, Galon J, Catteau A. Comparison of immune response assessment in colon cancer by immunoscore (automated digital pathology) and pathologist visual scoring. Cancers Basel. 2022;14(5):1170. doi:10.3390/cancers14051170. PMID: 35267475.
   PubMed Web of Science ®Google Scholar
• Willis J, Anders RA, Torigoe T, Hirohashi Y, Bifulco C, Zlobec I, Mlecnik B, Demaria S, Choi WT, Dundr P, et al. Multi-institutional evaluation of pathologists’ assessment compared to Immunoscore. Cancers Basel. 2023;15(16):4045. doi:10.3390/cancers15164045. PMID: 37627073.
   PubMed Web of Science ®Google Scholar
• Galon J, Lanzi A. Immunoscore and its introduction in clinical practice. Q J Nucl Med Mol Imaging. 2020;64:152–161. doi:10.23736/S1824-4785.20.03249-5. PMID: 32107902.
   PubMed Web of Science ®Google Scholar
• Lanzi A, Pages F, Lagorce-Pages C, Galon J. The consensus immunoscore: toward a new classification of colorectal cancer. Oncoimmunology. 2020;9:1789032. doi:10.1080/2162402X.2020.1789032. PMID: 32934885.
   PubMed Web of Science ®Google Scholar
• Marliot F, Lafontaine L, Galon J. Immunoscore assay for the immune classification of solid tumors: technical aspects, improvements and clinical perspectives. Methods Enzymol. 2020;636:109–128. doi:10.1016/bs.mie.2019.07.018. PMID: 32178816.
   PubMed Web of Science ®Google Scholar
• Marliot F, Pages F, Galon J. Usefulness and robustness of immunoscore for personalized management of cancer patients. Oncoimmunology. 2020;9:1832324. doi:10.1080/2162402X.2020.1832324. PMID: 33194318.
   PubMed Web of Science ®Google Scholar
• Pages F, Taieb J, Laurent-Puig P, Galon J. The consensus immunoscore in phase 3 clinical trials; potential impact on patient management decisions. Oncoimmunology. 2020;9:1812221. doi:10.1080/2162402X.2020.1812221. PMID: 32939329.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121:527–534. doi:10.1002/cncr.29072. PMID: 25332117.
   PubMed Web of Science ®Google Scholar
• Lewis C, Xun P, He K. Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer. 2016;24:1463–1471. doi:10.1007/s00520-015-2931-2. PMID: 26349575.
   PubMed Web of Science ®Google Scholar
• Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016;139:187–193. doi:10.1002/ijc.30053. PMID: 26914273.
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al. The AJCC TNM cancer staging manual. 8th ed. USA, New York: Springer Book.; 2017. p. 849–854.
   Google Scholar
• Pages F, Mlecnik B, Galon J. Quantifying immunoscore performance – authors’ reply. Lancet. 2018;392(10158):1624–1625. doi:10.1016/S0140-6736(18)32385-7. PMID: 30496076.
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39:11–26. doi:10.1016/j.immuni.2013.07.008. PMID: 23890060.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218. doi:10.1038/s41573-018-0007-y. PMID: 30610226.
   PubMed Web of Science ®Google Scholar
• Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco CB, Lugli A, Nagtegaal ID, Hartmann A, Van den Eynde M, Roehrl MHA, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019;37(4_suppl):487–487. doi:https://dx.doi.org/10.1200/JCO.2019.37.4_suppl.487. PMID: WOS:000489107600493.
   Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28–37. doi:10.4161/onci.1.1.17938. PMID: 22720209.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2013;2:e22789. doi:10.4161/onci.22789. PMID: 23482847.
   PubMed Web of Science ®Google Scholar
• Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876–887. doi:10.1016/S1470-2045(22)00274-1. PMID: 35636444.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Lauge C, Catteau A, Boquet I, Majdi A, et al. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer. EBioMedicine. 2023;92:104633. doi:10.1016/j.ebiom.2023.104633. PMID: 37244159.
   PubMed Web of Science ®Google Scholar
• Hijazi A, Antoniotti C, Cremolini C, Galon J. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response. Oncoimmunology. 2023;12:2243169. doi:10.1080/2162402X.2023.2243169. PMID: 37554310.
   PubMed Web of Science ®Google Scholar
• Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28:1872–1882. doi:10.1038/s41591-022-01916-x. PMID: 36038629.
   PubMed Web of Science ®Google Scholar
• Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31:921–929. doi:10.1016/j.annonc.2020.03.310. PMID: 32294529.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2013;6:117–122. doi:10.1007/s12307-012-0124-9. PMID: 23108700.
   PubMedGoogle Scholar
• Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81. doi:10.1016/j.immuni.2019.12.018. PMID: 31940273.
   PubMed Web of Science ®Google Scholar
• Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. PMID: 27121213.
   PubMed Web of Science ®Google Scholar
• Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84(4):981–987. doi:10.1189/jlb.1107773. PMID: 18559950.
   PubMed Web of Science ®Google Scholar
• Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31:214–234. doi:10.1038/modpathol.2017.156. PMID: 29192647.
   PubMed Web of Science ®Google Scholar
• Naidoo M, Gibbs P, Tie J. ctDNA and adjuvant therapy for colorectal cancer: time to Re-invent our treatment paradigm. Cancers Basel. 2021;13(2):346. doi:10.3390/cancers13020346. PMID: 33477814.
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology. 2014;3:e29179. doi:10.4161/onci.29179. PMID: 25083332.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology. 2014;3:e27456. doi:10.4161/onci.27456. PMID: 24800163.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38:3638–3651. doi:10.1200/jco.19.03205. PMID: 32897827.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, et al. Immunoscore is prognostic in low-risk and high-risk stage III colon carcinomas treated with adjuvant infusional fluorouracil, leucovorin, and oxaliplatin in a phase III trial. JCO Precis Oncol. 2022;6:e2200010. doi:10.1200/PO.22.00010. PMID: 35952316.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, et al. Contribution of immunoscore and molecular features to survival prediction in stage III colon cancer. JNCI Cancer Spectr. 2020;4:kaa023. doi:10.1093/jncics/pkaa023. PMID: 32455336.
   Web of Science ®Google Scholar
• Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial watch: naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4:e1026531. doi:10.1080/2162402x.2015.1026531. PMID: 26155408.
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. doi:10.1080/2162402X.2015.1008814. PMID: 26137403.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology. 2012;1:306–315. doi:10.4161/onci.19549. PMID: 22737606.
   PubMed Web of Science ®Google Scholar
• Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, et al. Trial watch: immunostimulation with toll-like receptor agonists in cancer therapy. Oncoimmunology. 2016;5:e1088631. doi:10.1080/2162402x.2015.1088631. PMID: 27141345.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunology. 2015;4:e974411. doi:10.4161/2162402X.2014.974411. PMID: 26137405.
   PubMed Web of Science ®Google Scholar
• Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial watch—oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5(2):e1117740. doi:10.1080/2162402x.2015.1117740. PMID: 27057469.
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2013;2:e23803. doi:10.4161/onci.23803. PMID: 23734328.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial watch—immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2016;5(2):e1115942. doi:10.1080/2162402x.2015.1115942. PMID: 27057468.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology. 2014;3:e29030. doi:10.4161/onci.29030. PMID: 25083328.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, et al. Trial watch: immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 2016;5:e1214790. doi:10.1080/2162402x.2016.1214790. PMID: 27757313.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial watch: immunostimulatory cytokines. Oncoimmunology. 2012;1(4):493–506. doi:10.4161/onci.20459. PMID: 22754768.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. doi:10.4161/onci.1.2.19026. PMID: 22720239.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2012;1:1557–1576. doi:10.4161/onci.22428. PMID: 23264902.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2013;2:e23510. doi:10.4161/onci.23510. PMID: 23687621.
   PubMed Web of Science ®Google Scholar
• Sun R, Henry T, Laville A, Carre A, Hamaoui A, Bockel S, Chaffai I, Levy A, Chargari C, Robert C, et al. Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? J Immunother Cancer. 2022;10(7):e004848. doi:10.1136/jitc-2022-004848. PMID: 35793875.
   PubMed Web of Science ®Google Scholar
• Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiol Imaging Cancer. 2019;1(2):e190031. doi:10.1148/rycan.2019190031. PMID: 33778682.
   PubMedGoogle Scholar
• Yao X, Sun C, Xiong F, Zhang X, Cheng J, Wang C, Ye Y, Hong N, Wang L, Liu Z, et al. Radiomic signature-based nomogram to predict disease-free survival in stage II and III colon cancer. Eur J Radiol. 2020;131:109205. doi:10.1016/j.ejrad.2020.109205. PMID: 32871292.
   PubMed Web of Science ®Google Scholar
• Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26:332–339. doi:10.1158/1078-0432.ccr-18-1851. PMID: 31413009.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. The role of the immune infiltrate in distinct cancer types and its clinical implications: lymphocytic infiltration in colorectal cancer. Cancer Treat Res. 2020;180:197–211. doi:10.1007/978-3-030-38862-1_7. PMID: 32215871.
   PubMedGoogle Scholar
• Marliot F, Chen X, Kirilovsky A, Sbarrato T, El Sissy C, Batista L, Van den Eynde M, Haicheur-Adjouri N, Anitei MG, Musina AM, et al. Analytical validation of the immunoscore and its associated prognostic value in patients with colon cancer. J Immunother Cancer. 2020;8:e000272. doi:10.1136/jitc-2019-000272. PMID: 32448799.
   PubMed Web of Science ®Google Scholar
• Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–1899. doi:10.1158/1078-0432.CCR-13-2830. PMID: 24691640.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5:e1057388. doi:10.1080/2162402X.2015.1057388. PMID: 26942067.
   PubMed Web of Science ®Google Scholar
• El Sissy C, Kirilovsky A, Lagorce Pages C, Marliot F, Custers PA, Dizdarevic E, Sroussi M, Castillo-Martin M, Haicheur N, Dermani M, et al. International validation of the immunoscore biopsy in patients with rectal cancer managed by a watch-and-wait strategy. J Clin Oncol. 2023. doi:10.1200/JCO.23.00586. JCO2300586; PMID: 37788410.
   Google Scholar
• El Sissy C, Kirilovsky A, Van den Eynde M, Musina AM, Anitei MG, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26:5198–5207. doi:10.1158/1078-0432.ccr-20-0337. PMID: WOS:000576795700019.
   PubMed Web of Science ®Google Scholar
• Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, et al. The immunoscore in localized urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathologic responses and overall survival. Cancers. 2021;13(3):494. doi:10.3390/cancers13030494. PMID: doi:10.3390/cancers13030494.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Galon J, Nayler S, Mlecnik B, Fugon A, Benn CA, Martel M, Cronje T, Smit T, Moosa F, et al. Tumour infiltrating lymphocytes in breast cancer: high levels of CD3, CD8 cells and immunoscore (R) are associated with pathological CR in patients receiving neo-adjuvant chemotherapy. Ann Oncol. 2020;31:S31–S32. doi:10.1016/j.annonc.2020.03.180. PMID: WOS:000538879300042.
   Web of Science ®Google Scholar
• Zhao Z, Zhao D, Xia J, Wang Y, Wang B. Immunoscore predicts survival in early-stage lung adenocarcinoma patients. Front Oncol. 2020;10:691. doi:10.3389/fonc.2020.00691. PMID: 32457841.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, et al. Pan-asian adapted ESMO clinical practice guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021;32:1496–1510. doi:10.1016/j.annonc.2021.08.1752. PMID: 34411693.
   PubMed Web of Science ®Google Scholar